By: admin On: September 11, 2021 In: Uncategorized Comments: 0

CAMBRIDGE, Mass.-(BUSINESS WIRE) -10, 2018– Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapy company, today announced that it has agreed with leading health insurers on the structure and key terms of value-based agreements (VBA) for the injection of onPAT™TRO (Patisiran) lipid complex, a first-of-its-kind RNA interference drug (RNAi) for the treatment of transthyretin heredin polyneuropathy. itary ( hATTR) Amyloidosis in adults. ONPATTRO, approved today by the U.S. Food and Drug Administration (FDA), is the first FDA-approved treatment to be available in the U.S. for this indication. ONPATTRO has been shown to improve polyneuropathy with a reversal of neuropathy impairment in a majority of patients, as measured by a change in the modified primary endpoint neuropathy Impairment Score +7 (mNIS+7) from the initial value of the MARKETING AUTHORIZATION study. In the largest controlled study in patients with hATTR amyloidosis with polyneuropathy, ONPATTRO was also shown to improve quality of life, as measured by patients` reported assessment of neuropathy Quality of Life (QoL-DN), which reduces autonomic symptoms and improves activities of daily living. However, it turned out that a lack of infrastructure to monitor patients and articulate their clinical outcomes with insurance rights makes value-based contracts difficult. The partnership with paying agencies under these agreements aims to enhance the security of their investment and accelerate coverage decisions for patients.

The agreements are structured in such a way that they combine ONPATTRO`s performance in real terms with financial terms.. . . .

Trackback URL: